Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30711617 | 0.87 | KDM4E (0.54) | MAPTALDH1A1KDM4EPOLBLMNA | |
| SCHEMBL29174252 | 0.86 | MAPT (0.49) | MAPTALDH1A1KDM4EPOLBLMNA | |
| SCHEMBL27033921 | 0.83 | LMNA (0.47) | MAPTALDH1A1KDM4EPOLBLMNA | |
| SCHEMBL1197644 | 0.81 | KMO (0.50) | MAPTALDH1A1KDM4EPOLBLMNA | |
| SCHEMBL12530682 | 0.80 | LMNA (0.48) | MAPTALDH1A1KDM4EPOLBLMNA | |
| SCHEMBL9517884 | 0.79 | PTGDR2 (0.41) | MAPTALDH1A1KDM4EPOLBPTGDR2 | |
| SCHEMBL27033354 | 0.79 | LMNA (0.57) | MAPTALDH1A1KDM4EPOLBLMNA | |
| SCHEMBL4591133 | 0.77 | KDM4E (1.00) | MAPTALDH1A1KDM4EPOLBLMNA | |
| SCHEMBL26111441 | 0.77 | ALDH1A1 (0.62) | MAPTALDH1A1KDM4EPOLBLMNA | |
| SCHEMBL4893880 | 0.77 | ALDH1A1 (0.62) | MAPTALDH1A1KDM4EPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-21 | — | — | US | disclosed |
| EP-4308228-A1 | PLASMA KALLIKREIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117396474-A | Plasma kallikrein inhibitors | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| WO-2022197756-A1 | PLASMA KALLIKREIN INHIBITORS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-8889674-B2 | Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism | SHIONOGI & CO., LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| US-8889674-B2 | Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism | SHIONOGI & CO., LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| EP-2404902-A1 | PIPERIDINE AND PYRROLIDINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISM | Shionogi&Co., Ltd. (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-20110319412-A1 | PIPERIDINE AND PYRROLIDINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISM | SHIONOGI & CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319412-A1 | PIPERIDINE AND PYRROLIDINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISM | SHIONOGI & CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-1045844-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2002-08-21 | — | — | EP | disclosed |
| EP-1045844-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2000-10-25 | — | — | EP | disclosed |
| US-5932590-A | PEPTIDOMIMETIC IMIDAZOLYL-CONTAINING 1,2,3,4-TETRAHYDRO-QUINOLINES OR AN ANALOGOUS 3-BENZAZEPINES; ANTICARCINOGENIC AND-PROLIFERATIVE AGENTS; POLYCYSTIC KIDNEY DISEASE; RESTENOSIS PREVENTION; HEPATITIS; RETINAL VASCULARZATION | MERCK & CO., INC. (US) | 1999-08-03 | — | — | US | disclosed |
| WO-1999028314-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-06-10 | — | — | WO | disclosed |
| US-3994874-A | ANTIBACTERIAL | RICHARDSON-MERRELL INC. (US) | 1976-11-30 | — | — | US | disclosed |
| US-3956287-A | BACTERICIDES | RICHARDSON-MERRELL INC. (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | MAPT 3323/4885ALDH1A1 3175/4885KDM4E 838/4885 |
| US-20110319412-A1 | PIPERIDINE AND PYRROLIDINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISM | NPY5R, NPY1R, NPY2R | MAPT 4471/4885ALDH1A1 3975/4885KDM4E 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.